- Email: [email protected]
Research of Gestrinone-Related Abnormal Uterine Bleeding and the Intervention in the Treatment: A Multi-Center, Randomized, Controlled Clinical Trial
S64
Abstracts / Journal of Minimally Invasive Gynecology 23 (2016) S1–S252
urinary retention that resolved in the 2nd and 3rd week postoperatively. Five patients had subileus, one patient who underwent laparotomy for ureteroneocystostomy had temporary voiding problems due to kinking of the intramural part of the contralateral ureter. There were no perforations, fistulas, or infections. Blood transfusion was required in only one of the cases. Conclusion: Colloboration of a specialized team of surgeons before, during and after this challenging surgery reduces complications to a minimum. 154
Open Communications 12 - Endometriosis (3:25 PM - 5:05 PM)
p =0.011). The incidence of abnormal uterine bleeding in participants with abnormal ovarian volume results from ovarian cyst or ovarian surgery was significantly lower than those with normal ovarian volume (OR=0.304, p =0.018). (3)After the treatment of three month, there were no significant difference in alanine transaminase level between the groups(P >0.05). Conclusion: Double dose of gestrinone in the first month could significantly decrease the incidence of gestrinone -related abnormal uterine bleeding. 155
Open Communications 12 - Endometriosis (3:25 PM - 5:05 PM)
3:32 PM – GROUP A Research of Gestrinone-Related Abnormal Uterine Bleeding and the Intervention in the Treatment: A Multi-Center, Randomized, Controlled Clinical Trial Wang S, Duan H. Minimally Invasive Gynecology, Beijing Obstetrics and Gynecology Hospital, Beijing, China Study Objective: Investigate the incidence, influencing factors and intervention of gestrinone -related abnormal uterine bleeding at different dosage. Design: Prospective multicenter, randomized, control clinical trial. Setting: Academic affiliated community hospital Patients: 195 women with endometriosis or adenomyosis from June 2011 to November 2013. Intervention: The subjects were randomized into three groups with oral administration of gestrinone, 2.5mg dose at one time; twice a week group(Group A): 67 cases with oral administration twice a week last two months; double dose first month group(Group B): 67 cases with oral administration triple times a week at first month, then twice a week for two months; three times a week group(Group C): 61 cases with oral administration three times a week last three months. Measurements and Main Results: (1) Three months after, the incidence of abnormal uterine bleeding in Group A was 30 %, in Group B and Group C were 7% and 16% respectively, there were significant difference between three groups(p \0.05)The incidence in Group B was the most lower. (2) Univariate analysis showed that the dosage and ovarian size were the significant factors for abnormal uterine bleeding (OR=0.461, p =0.003; OR=0.303, p =0.016); logistic regression analysis demonstrated that the risk of abnormal uterine bleeding in Group B was the lowest when compared with Group A and Group C, the risk in Group A was 5-fold higher than that in Group B(OR=0.211,
3:39 PM – GROUP A Urinary Tract Endometriosis: Review of Four Decades of Evidence and Updates Fatehchehr S,1 Hosseini Nasab S,2 Kohanteb PA.3 1Department of Obstetrics and Gynecology, Division of Female Pelvic Medicine and Reconstructive Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 2University of Texas, Health Science Center at Houston, Houston, Texas; 3Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois
Table 1. Symptoms of UTE in Bladder and Ureter [6] Symptoms of vesical endometriosis
Frequency (%)
1. 2. 3. 4. 5. 6. 7. 8.
41-71 41-78 14-21 38-78 50-75 21 19-30 50
Frequency Urgency Dysuria Suprapubic pain Nocturia Urge incontinence Hematuria Pelvic Mass
Symptoms of ureteral endometriosis 1. 2. 3. 4. 5. 6. 7.
Flank Pain Abdominal pain Dysuria Gross hematuria Uremia Pelvic mass Asymptomatic
17-26 24-45 9-15 13-18 2-4 13-14 50
Table 2. UTE diagnostic modalities UTE diagnostic modalities
Sensitivity (%)
Specificity (%)
1. Kidney Ureter Bladder X-Ray (KUB) [21] 2. Ultrasonography (US): [24,25,26] (Transabdominal pelvic ultrasound [21] and Transvaginal ultrasound [27,28,29]) 3. Cystoscopy [30] 4. Ureteroscopy [32,33,34] 5. Intravenous pyelography (IVP) [30,35,36 6. Magnetic resonance imaging (MRI). [30,35,36,28,29] 7. Retrograde urography [36] 8. Intravenous urography [40,36] 9. Computed tomography (CT-Scan) [36,37,41] 10. mercaptoacetyltriglycine (MAG3) renography [21,42] (Radioisotope) renography [43]
60 [22,23]* 73-83[25,26]
77 [22,23]* 86-98[24,25,26]
95 [31] N/A 85-90 [37,38]* 90 [39] N/A N/A 72.2 [37] 91[43]*
87-93 [31] N/A 95-100 [37,38]* 91 [39] N/A N/A 100 [37] 84 [43]*
* Evaluation for obstructive uropathy
Abstracts / Journal of Minimally Invasive Gynecology 23 (2016) S1–S252
urinary retention that resolved in the 2nd and 3rd week postoperatively. Five patients had subileus, one patient who underwent laparotomy for ureteroneocystostomy had temporary voiding problems due to kinking of the intramural part of the contralateral ureter. There were no perforations, fistulas, or infections. Blood transfusion was required in only one of the cases. Conclusion: Colloboration of a specialized team of surgeons before, during and after this challenging surgery reduces complications to a minimum. 154
Open Communications 12 - Endometriosis (3:25 PM - 5:05 PM)
p =0.011). The incidence of abnormal uterine bleeding in participants with abnormal ovarian volume results from ovarian cyst or ovarian surgery was significantly lower than those with normal ovarian volume (OR=0.304, p =0.018). (3)After the treatment of three month, there were no significant difference in alanine transaminase level between the groups(P >0.05). Conclusion: Double dose of gestrinone in the first month could significantly decrease the incidence of gestrinone -related abnormal uterine bleeding. 155
Open Communications 12 - Endometriosis (3:25 PM - 5:05 PM)
3:32 PM – GROUP A Research of Gestrinone-Related Abnormal Uterine Bleeding and the Intervention in the Treatment: A Multi-Center, Randomized, Controlled Clinical Trial Wang S, Duan H. Minimally Invasive Gynecology, Beijing Obstetrics and Gynecology Hospital, Beijing, China Study Objective: Investigate the incidence, influencing factors and intervention of gestrinone -related abnormal uterine bleeding at different dosage. Design: Prospective multicenter, randomized, control clinical trial. Setting: Academic affiliated community hospital Patients: 195 women with endometriosis or adenomyosis from June 2011 to November 2013. Intervention: The subjects were randomized into three groups with oral administration of gestrinone, 2.5mg dose at one time; twice a week group(Group A): 67 cases with oral administration twice a week last two months; double dose first month group(Group B): 67 cases with oral administration triple times a week at first month, then twice a week for two months; three times a week group(Group C): 61 cases with oral administration three times a week last three months. Measurements and Main Results: (1) Three months after, the incidence of abnormal uterine bleeding in Group A was 30 %, in Group B and Group C were 7% and 16% respectively, there were significant difference between three groups(p \0.05)The incidence in Group B was the most lower. (2) Univariate analysis showed that the dosage and ovarian size were the significant factors for abnormal uterine bleeding (OR=0.461, p =0.003; OR=0.303, p =0.016); logistic regression analysis demonstrated that the risk of abnormal uterine bleeding in Group B was the lowest when compared with Group A and Group C, the risk in Group A was 5-fold higher than that in Group B(OR=0.211,
3:39 PM – GROUP A Urinary Tract Endometriosis: Review of Four Decades of Evidence and Updates Fatehchehr S,1 Hosseini Nasab S,2 Kohanteb PA.3 1Department of Obstetrics and Gynecology, Division of Female Pelvic Medicine and Reconstructive Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 2University of Texas, Health Science Center at Houston, Houston, Texas; 3Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois
Table 1. Symptoms of UTE in Bladder and Ureter [6] Symptoms of vesical endometriosis
Frequency (%)
1. 2. 3. 4. 5. 6. 7. 8.
41-71 41-78 14-21 38-78 50-75 21 19-30 50
Frequency Urgency Dysuria Suprapubic pain Nocturia Urge incontinence Hematuria Pelvic Mass
Symptoms of ureteral endometriosis 1. 2. 3. 4. 5. 6. 7.
Flank Pain Abdominal pain Dysuria Gross hematuria Uremia Pelvic mass Asymptomatic
17-26 24-45 9-15 13-18 2-4 13-14 50
Table 2. UTE diagnostic modalities UTE diagnostic modalities
Sensitivity (%)
Specificity (%)
1. Kidney Ureter Bladder X-Ray (KUB) [21] 2. Ultrasonography (US): [24,25,26] (Transabdominal pelvic ultrasound [21] and Transvaginal ultrasound [27,28,29]) 3. Cystoscopy [30] 4. Ureteroscopy [32,33,34] 5. Intravenous pyelography (IVP) [30,35,36 6. Magnetic resonance imaging (MRI). [30,35,36,28,29] 7. Retrograde urography [36] 8. Intravenous urography [40,36] 9. Computed tomography (CT-Scan) [36,37,41] 10. mercaptoacetyltriglycine (MAG3) renography [21,42] (Radioisotope) renography [43]
60 [22,23]* 73-83[25,26]
77 [22,23]* 86-98[24,25,26]
95 [31] N/A 85-90 [37,38]* 90 [39] N/A N/A 72.2 [37] 91[43]*
87-93 [31] N/A 95-100 [37,38]* 91 [39] N/A N/A 100 [37] 84 [43]*
* Evaluation for obstructive uropathy